FDA speaks out on the future of cannabis-containing food products
On 17 June 2019, the U.S. Food and Drug Administration (FDA) released a statement regarding its current, science-based stance on the use of cannabis or cannabis-derived compounds, including cannabidiol (CBD), in various products including food.
Here is what the agency’s statement says in regards to cannabis in food:
- Food, including dietary supplements, is regulated differently [vs. drugs], but with the same overarching goal of protecting consumers. Among other things, it is currently illegal to put into interstate commerce a food to which CBD has been added, or to market CBD as, or in, a dietary supplement. Essentially, the relevant statutory provisions prohibit these uses of CBD because CBD was the subject of substantial clinical investigations into its potential medical uses before it was added to foods (including dietary supplements), and, separately, because CBD is the active ingredient in Epidiolex, an FDA-approved prescription drug product to treat rare, severe forms of epilepsy.
- At the same time, the FDA recognizes that there is substantial public interest in marketing and accessing CBD in food, including dietary supplements. The statutory provisions that currently prohibit marketing CBD in these forms also allow the FDA to issue a regulation creating an exception, and some stakeholders have asked that the FDA consider issuing such a regulation to allow for the marketing of CBD in conventional foods or as a dietary supplement, or both. This raises important and challenging questions of regulatory policy and public health.
FDA Statement: «FDA is Committed to Sound, Science-based Policy on CBD»
Zu diesem Thema siehe auch foodnavigator-usa.com
Zur rechtlichen Situation in der Schweiz, siehe News vom 21. Juni 2019